Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
In order to clarify the association between HBV mutations appearing before and during
interferon therapy and the therapeutic effects, serial serum samples from 100 HBeAg-positive
CHB patients undergoing peginterferon alfa-2a therapy will be collected and analyzed for the
mutations of preS/S gene and BCP-preC/C region, particularly for the deletion mutations.
Furthermore, Real-Time PCR will be performed to measure the ratios of wild-type HBV and
deletion mutant HBV before and at the end of peginterferon alfa-2a therapy. Finally,
statistical analysis will be done to elucidate whether the mutations of preS/S gene and
BCP-preC/C region have any relation with the therapeutic effect of peginterferon alfa-2a.